Succinate and its G-protein-coupled receptor stimulates osteoclastogenesis

Nature Communications

Volumn 8, Issue , 2017, Pages

  Guo, Yuqi ^a   Xie, Chengzhi ^a   Li, Xiyan ^b   Yang, Jian ^a   Yu, Tao ^a,c   Zhang, Ruohan ^a   Zhang, Tianqing ^a   Saxena, Deepak ^a   Snyder, Michael ^b   Wu, Yingjie ^c,d   Li, Xin ^a,e  

^a NEW YORK UNIVERSITY COLLEGE OF DENTISTRY   (United States)

^b STANFORD UNIVERSITY   (United States)

^c Institute for Genomic Engineered Animal Models of Human Diseases   (China)

^d DALIAN MEDICAL UNIVERSITY   (China)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CALCITONIN RECEPTOR; CATHEPSIN K; CYTOKINE; CYTOMEGALOVIRUS ANTIGEN PP65; FUMARIC ACID; G PROTEIN COUPLED RECEPTOR; GLUCOSE; GLUTAMATE DEHYDROGENASE; HISTONE H3; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 13; INTERLEUKIN 1BETA; INTERLEUKIN 4; ISOCITRATE DEHYDROGENASE; MALIC ACID; METFORMIN; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN P50; SMALL INTERFERING RNA; SOMATOMEDIN C RECEPTOR; SUCCINATE DEHYDROGENASE; SUCCINIC ACID; TRANSCRIPTION FACTOR NFATC1; TRAP5B PROTEIN; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; GPR91 PROTEIN, MOUSE;

ACTIVATION ENERGY; BONE; CELLS AND CELL COMPONENTS; CHRONIC WASTING DISEASE; DIABETES; DIGESTIVE SYSTEM DISORDER; GENETIC ANALYSIS; LIGAND; METABOLITE; PROTEIN; RODENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW STROMA CELL; BONE METABOLISM; CELL LINEAGE; CITRIC ACID CYCLE; CONTROLLED STUDY; CYTOSOL; FRACTURE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; METABOLIC DISORDER; METABOLOMICS; MITOCHONDRION; MORPHOMETRY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOCLASTOGENESIS; OSTEOLYSIS; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BONE DEVELOPMENT; BONE MARROW CELL; C57BL MOUSE; CELL DIFFERENTIATION; CELL LINE; CYTOLOGY; GENETICS; KNOCKOUT MOUSE; MALE; MESENCHYMAL STROMA CELL; METABOLISM; OSTEOCLAST; PATHOLOGY; PHYSIOLOGY; RAW 264.7 CELL LINE;

MUS;

ANIMALS; BONE MARROW CELLS; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE; CITRIC ACID CYCLE; DIABETES MELLITUS, TYPE 2; HYPERGLYCEMIA; MALE; MESENCHYMAL STROMAL CELLS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NF-KAPPA B; OSTEOCLASTS; OSTEOGENESIS; RANK LIGAND; RAW 264.7 CELLS; RECEPTORS, G-PROTEIN-COUPLED; SUCCINIC ACID;

EID: 85020037237     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms15621     Document Type: Article

References (69)

1. Farr, J. N. et al. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J. Bone Miner. Res. 29, 787-795 (2014).
2. Raggatt, L. J. & Partridge, N. C. Cellular and molecular mechanisms of bone remodeling. J. Biol. Chem. 285, 25103-25108 (2010).
3. Eriksen, E. F. Cellular mechanisms of bone remodeling. Rev. Endocr. Metab. Disord. 11, 219-227 (2010).
4. Feng, X. & McDonald, J. M. Disorders of bone remodeling. Annu. Rev. Pathol. 6, 121-145 (2011).
5. Boyle, W. J., Simonet, W. S. & Lacey, D. L. Osteoclast differentiation and activation. Nature 423, 337-342 (2003).
6. Kim, H. N., Lee, J. H., Jin, W. J. & Lee, Z. H. Alpha-Tocopheryl succinate inhibits osteoclast formation by suppressing receptor activator of nuclear factor-kappaB ligand (RANKL) expression and bone resorption. J. Bone Metab. 19, 111-120 (2012).
7. Shanbhogue, V. V. et al. Compromised cortical bone compartment in type 2 diabetes mellitus patients with microvascular disease. Eur. J. Endocrinol. 174, 115-124 (2016).
8. Patsch, J. M. et al. Increased cortical porosity in type 2 diabetic postmenopausal women with fragility fractures. J. Bone. Miner. Res. 28, 313-324 (2013).
9. Heilmeier, U. et al. Cortical bone laminar analysis reveals increased midcortical and periosteal porosity in type 2 diabetic postmenopausal women with history of fragility fractures compared to fracture-free diabetics. Osteoporos. Int. 27, 2791-2802 (2016).
10. Wongdee, K. & Charoenphandhu, N. Update on type 2 diabetes-related osteoporosis. World J. Diabetes 6, 673-678 (2015).
11. Agarwal, S. et al. Diminished chondrogenesis and enhanced osteoclastogenesis in leptin-deficient diabetic mice (ob/ob) impair pathologic, trauma-induced heterotopic ossification. Stem Cells Dev. 24, 2864-2872 (2015).
12. Silva, J. A. et al. Periodontal disease-Associated compensatory expression of osteoprotegerin is lost in type 1 diabetes mellitus and correlates with alveolar bone destruction by regulating osteoclastogenesis. Cells Tissues Organs 196, 137-150 (2012).
13. Kawashima, Y. et al. Type 2 diabetic mice demonstrate slender long bones with increased fragility secondary to increased osteoclastogenesis. Bone 44, 648-655 (2009).
14. Wittrant, Y. et al. High d()glucose concentration inhibits RANKL-induced osteoclastogenesis. Bone 42, 1122-1130 (2008).
15. Xu, J., Yue, F., Wang, J., Chen, L. & Qi, W. High glucose inhibits receptor activator of nuclear factorkappaB ligand-induced osteoclast differentiation via downregulation of vATPase V0 subunit d2 and dendritic cell specific transmembrane protein. Mol. Med. Rep. 11, 865-870 (2015).
16. Li, X., Guo, Y., Yan, W., Snyder, M. P. & Li, X. Metformin improves diabetic bone health by re-balancing catabolism and nitrogen disposal. PLoS ONE 10, e0146152 (2015).
17. Matsumoto, M. et al. Succinate increases in the vitreous fluid of patients with active proliferative diabetic retinopathy. Am. J. Ophthalmol. 153, 896-902 e891 (2012).
18. He, W. et al. Citric acid cycle intermediates as ligands for orphan G-proteincoupled receptors. Nature 429, 188-193 (2004).
19. Li, T. et al. ERK1/2/COX-2/PGE2 signaling pathway mediates GPR91-dependent VEGF release in streptozotocin-induced diabetes. Mol. Vis. 20, 1109-1121 (2014).
20. Sapieha, P. et al. The succinate receptor GPR91 in neurons has a major role in retinal angiogenesis. Nat. Med. 14, 1067-1076 (2008).
21. Rubic, T. et al. Triggering the succinate receptor GPR91 on dendritic cells enhances immunity. Nat. Immunol. 9, 1261-1269 (2008).
22. Weitzmann, M. N. et al. T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent andindependent mechanisms. J. Bone. Miner. Res. 16, 328-337 (2001).
23. Fernandez, A. M. et al. Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes. Genes Dev. 15, 1926-1934 (2001).
24. Cuetara, B. L., Crotti, T. N., ODonoghue, A. J. & McHugh, K. P. Cloning and characterization of osteoclast precursors from the RAW264.7 cell line in vitro. Cell Dev. Biol. Anim. 42, 182-188 (2006).
25. Srinivasan, S. & Avadhani, N. G. Hypoxia-mediated mitochondrial stress in RAW264.7 cells induces osteoclast-like TRAP-positive cells. Ann. N. Y. Acad. Sci. 1117, 51-61 (2007).
26. Lindunger, A., MacKay, C. A., Ek-Rylander, B., Andersson, G. & Marks, Jr S. C. Histochemistry and biochemistry of tartrate-resistant acid phosphatase (TRAP) and tartrate-resistant acid adenosine triphosphatase (TrATPase) in bone, bone marrow and spleen: implications for osteoclast ontogeny. Bone Miner. 10, 109-119 (1990).
27. Baron, R. Molecular mechanisms of bone resorption by the osteoclast. Anat. Rec. 224, 317-324 (1989).
28. Christenson, R. H. Biochemical markers of bone metabolism: An overview. Clin. Biochem. 30, 573-593 (1997).
29. Hayman, A. R. Tartrate-resistant acid phosphatase (TRAP) and the osteoclast/immune cell dichotomy. Autoimmunity 41, 218-223 (2008).
30. Yamada, A. et al. Interleukin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts. Immunology 120, 573-579 (2007).
31. Stein, N. C. et al. Interleukin-4 and interleukin-13 stimulate the osteoclast inhibitor osteoprotegerin by human endothelial cells through the STAT6 pathway. J. Bone Miner. Res. 23, 750-758 (2008).
32. Hamel, D. et al. G-protein-coupled receptor 91 and succinate are key contributors in neonatal postcerebral hypoxia-ischemia recovery. Arterioscler. Thromb. Vasc. Biol. 34, 285-293 (2014).
33. Spath, B., Hansen, A., Bokemeyer, C. & Langer, F. Succinate reverses in-vitro platelet inhibition by acetylsalicylic acid and P2Y receptor antagonists. Platelets 23, 60-68 (2012).
34. Bhuniya, D. et al. Discovery of a potent and selective small molecule hGPR91 antagonist. Bioorg. Med. Chem. Lett. 21, 3596-3602 (2011).
35. Mai, Q. G. et al. Metformin stimulates osteoprotegerin and reduces RANKL expression in osteoblasts and ovariectomized rats. J. Cell. Biochem. 112, 2902-2909 (2011).
36. Yamaguchi, T. Bone fragility in type 2 diabetes mellitus. World J. Orthop. 1, 3-9 (2010).
37. Manolagas, S. C. From estrogen-centric to aging and oxidative stress: A revised perspective of the pathogenesis of osteoporosis. Endocr. Rev. 31, 266-300 (2010).
38. Hamada, Y., Fujii, H. & Fukagawa, M. Role of oxidative stress in diabetic bone disorder. Bone 45, S35-S38 (2009).
39. Manolagas, S. C. & Almeida, M. Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism. Mol. Endocrinol. 21, 2605-2614 (2007).
40. Ohnishi, T. et al. Oxidative stress causes alveolar bone loss in metabolic syndrome model mice with type 2 diabetes. J. Periodontal. Res. 44, 43-51 (2009).
41. Urao, N. & Ushio-Fukai, M. Redox regulation of stem/progenitor cells and bone marrow niche. Free Radic. Biol. Med. 54, 26-39 (2013).
42. Na, U. et al. The LYR factors SDHAF1 and SDHAF3 mediate maturation of the iron-sulfur subunit of succinate dehydrogenase. Cell Metab. 20, 253-266 (2014).
43. Van Vranken, J. G. et al. SDHAF4 promotes mitochondrial succinate dehydrogenase activity and prevents neurodegeneration. Cell Metab. 20, 241-252 (2014).
44. Slane, B. G. et al. Mutation of succinate dehydrogenase subunit C results in increased O2.-, oxidative stress, and genomic instability. Cancer Res. 66, 7615-7620 (2006).
45. Sinhorin, V. D. et al. Succinate causes oxidative damage through N-methyl-Daspartate-mediated mechanisms. Brain Res. 1051, 66-71 (2005).
46. Rajeswarareddy, S., Lavany, T., Narasimhulu, G. & Sathyavelureddy, K. Effect of pimpinellatirupatiensison oxidative enzymes in STZ-induced diabetic rat kidney. Iran. J. Pharmaceut. Res. 11, 277-286 (2012).
47. Fedotcheva, N. I., Sokolov, A. P. & Kondrashova, M. N. Nonezymatic formation of succinate in mitochondria under oxidative stress. Free Radic. Biol. Med. 41, 56-64 (2006).
48. Brookes, P. S., Freeman, R. S. & Barone, M. C. A shortcut to mitochondrial signaling and pathology: A commentary on Nonenzymatic formation of succinate in mitochondria under oxidative stress. Free Radic. Biol. Med. 41, 41-45 (2006).
49. Tonna, E. A. & Pillsbury, N. Changes in the osteoblastic and mitochondrial population of aging periosteum. Nature 183, 337-338 (1959).
50. Mills, E. & ONeill, L. A. Succinate: A metabolic signal in inflammation. Trends Cell Biol. 24, 313-320 (2014).
51. Görlach, A. & Bonello, S. The cross-Talk between NF-kB and HIF-1: further evidence for a significant liaison. Biochem. J. 412, e17-e19 (2008).
52. Indo, Y. et al. Metabolic regulation of osteoclast differentiation and function. J. Bone Miner. Res. 28, 2392-2399 (2013).
53. Tannahill, G. M. et al. Succinate is an inflammatory signal that induces IL-1[bgr] through HIF-1[agr]. Nature 496, 238-242 (2013).
54. Dahia, P. L. et al. A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 1, 72-80 (2005).
55. Yaturu, S., Bryant, B. & Jain, S. K. Thiazolidinedione treatment decreases bone mineral density in type 2 diabetic men. Diabetes Care 30, 1574-1576 (2007).
56. Taylor, S. I., Blau, J. E. & Rother, K. I. Possible adverse effects of SGLT2 inhibitors on bone. Lancet Diabetes Endocrinol. 3, 8-10 (2015).
57. Vestergaard, P., Rejnmark, L. & Mosekilde, L. Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk. Diabetologia 48, 1292-1299 (2005).
58. Zhen, D., Chen, Y. & Tang, X. Metformin reverses the deleterious effects of high glucose on osteoblast function. J. Diabetes Complications 24, 334-344 (2010).
59. Gao, Y., Li, Y., Xue, J., Jia, Y. & Hu, J. Effect of the anti-diabetic drug metformin on bone mass in ovariectomized rats. Eur. J. Pharmacol. 635, 231-236 (2010).
60. Molinuevo, M. S. et al. Effect of metformin on bone marrow progenitor cell differentiation: in vivo and in vitro studies. J. Bone Miner. Res. 25, 211-221 (2010).
61. Lee, Y. S. et al. AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts. Bone 47, 926-937 (2010).
62. Moiseeva, O., Deschenes-Simard, X., Pollak, M. & Ferbeyre, G. Metformin, aging and cancer. Aging (Albany NY) 5, 330-331 (2013).
63. Zeevalk, G. D., Derr-Yellin, E. & Nicklas, W. J. NMDA receptor involvement in toxicity to dopamine neurons in vitro caused by the succinate dehydrogenase inhibitor 3-nitropropionic acid. J. Neurochem. 64, 455-458 (1995).
64. Tai, E. S. et al. Insulin resistance is associated with a metabolic profile of altered protein metabolism in Chinese and Asian-Indian men. Diabetologia 53, 757-767 (2010).
65. Uno, K., Takarada, T., Hinoi, E. & Yoneda, Y. Glutamate is a determinant of cellular proliferation through modulation of nuclear factor E2 p45-related factor-2 expression in osteoblastic MC3T3-E1 cells. J. Cell Physiol. 213, 105-114 (2007).
66. Takarada-Iemata, M. et al. Glutamate preferentially suppresses osteoblastogenesis than adipogenesis through the cystine/glutamate antiporter in mesenchymal stem cells. J. Cell Physiol. 226, 652-665 (2011).
67. Merle, B., Itzstein, C., Delmas, P. D. & Chenu, C. NMDA glutamate receptors are expressed by osteoclast precursors and involved in the regulation of osteoclastogenesis. J. Cell Biochem. 90, 424-436 (2003).
68. Zhang, G. et al. A delivery system targeting bone formation surfaces to facilitate RNAi-based anabolic therapy. Nat. Med. 18, 307-314 (2012).
69. vant Hof, R., Rose, L. & Daroszewska, A. Open source software for semiautomated histomorphometry of bone resorption and formation parameters. Bone 99, 69-79 (2013).